NASDAQ:SNNA - Sienna Biopharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$15.91 -0.99 (-5.86 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$16.90
Today's Range$15.61 - $16.92
52-Week Range$13.37 - $29.25
Volume35,200 shs
Average Volume87,842 shs
Market Capitalization$350.37 million
P/E Ratio-3.10
Dividend YieldN/A
BetaN/A
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.

Receive SNNA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNNA
CUSIPN/A
Phone818-629-2256

Debt

Debt-to-Equity RatioN/A
Current Ratio6.84
Quick Ratio6.84

Price-To-Earnings

Trailing P/E Ratio-3.10
Forward P/E Ratio-5.47
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.44 per share
Price / Book3.58

Profitability

EPS (Most Recent Fiscal Year)($5.19)
Net Income$-50,540,000.00
Net MarginsN/A
Return on Equity-110.53%
Return on Assets-45.87%

Miscellaneous

Employees47
Outstanding Shares20,730,000
Market Cap$350.37

The Truth About Cryptocurrencies

Sienna Biopharmaceuticals (NASDAQ:SNNA) Frequently Asked Questions

What is Sienna Biopharmaceuticals' stock symbol?

Sienna Biopharmaceuticals trades on the NASDAQ under the ticker symbol "SNNA."

How were Sienna Biopharmaceuticals' earnings last quarter?

Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) issued its quarterly earnings data on Monday, May, 14th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by $0.15. View Sienna Biopharmaceuticals' Earnings History.

What price target have analysts set for SNNA?

4 brokerages have issued 12-month price objectives for Sienna Biopharmaceuticals' shares. Their forecasts range from $21.00 to $50.00. On average, they anticipate Sienna Biopharmaceuticals' share price to reach $32.25 in the next twelve months. This suggests a possible upside of 102.7% from the stock's current price. View Analyst Ratings for Sienna Biopharmaceuticals.

What is the consensus analysts' recommendation for Sienna Biopharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sienna Biopharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Sienna Biopharmaceuticals' key competitors?

Who are Sienna Biopharmaceuticals' key executives?

Sienna Biopharmaceuticals' management team includes the folowing people:
  • Dr. Frederick C. Beddingfield III, CEO, Pres & Director (Age 53)
  • Dr. Todd Harris, Head of Corp. Devel. & Director (Age 39)
  • Mr. John W. Smither, Chief Financial Officer (Age 65)
  • Mr. Majed Kheir, VP of Operations (Age 40)
  • Dr. Silvio Traversa BSc Ph.D., Chief Scientific Officer (Age 48)

When did Sienna Biopharmaceuticals IPO?

(SNNA) raised $64 million in an IPO on Thursday, July 27th 2017. The company issued 4,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets acted as the underwriters for the IPO.

Has Sienna Biopharmaceuticals been receiving favorable news coverage?

News headlines about SNNA stock have trended somewhat positive this week, Accern reports. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sienna Biopharmaceuticals earned a media sentiment score of 0.10 on Accern's scale. They also gave news coverage about the company an impact score of 45.85 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Sienna Biopharmaceuticals?

Shares of SNNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sienna Biopharmaceuticals' stock price today?

One share of SNNA stock can currently be purchased for approximately $15.91.

How big of a company is Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals has a market capitalization of $350.37 million. The company earns $-50,540,000.00 in net income (profit) each year or ($5.19) on an earnings per share basis. Sienna Biopharmaceuticals employs 47 workers across the globe.

How can I contact Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals' mailing address is 30699 Russell Ranch Road Suite 140, Westlake Village CA, 91362. The company can be reached via phone at 818-629-2256 or via email at [email protected]


MarketBeat Community Rating for Sienna Biopharmaceuticals (NASDAQ SNNA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  177
MarketBeat's community ratings are surveys of what our community members think about Sienna Biopharmaceuticals and other stocks. Vote "Outperform" if you believe SNNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Featured Article: Closed-End Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.